Journal of global antimicrobial resistance · 2026
Relebactam enhances the activity of imipenem against Burkholderia cepacia complex isolates.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Liang Lianzhu, Mane Joel, Hilbert David W, Motyl Mary, Lange Henry S, McKenney Dave, Estabrook Mark, DeRyke C Andrew, Sahm Daniel, Young Katherine
Аннотация
BACKGROUND: Burkholderia cepacia complex (BCC) is a group of ≥21 related organisms, including B. cepacia, Burkholderia cenocepacia, and Burkholderia multivorans. BCC can cause opportunistic infections in people who are immunocompromised and those with comorbidities or lung conditions. BCC exhibits intrinsic and acquired resistance to antimicrobial agents; additional treatment options may improve patient outcomes.
METHODS: BCC isolates were collected as part of the Study for Monitoring Antimicrobial Resistance Trends global surveillance program from 2016 to 2019 and 2020 to 2022. Susceptibility of isolates to imipenem and imipenem/relebactam was tested in vitro, and the effects of imipenem/cilastatin/relebactam on BCC burden were evaluated in vivo.
RESULTS: In total, 346 and 293 BCC isolates were collected from 2016 to 2019 and 2020 to 2022, respectively, the most common were B. cepacia (2016-2019: n = 145/346; 2020-2022: n = 124/293) and B. cenocepacia (2016-2019: n = 137/346; 2020-2022: n = 119/293). In vitro, imipenem/relebactam reduced 50% and 90% minimum inhibitory concentrations for BCC isolates by 8-16-fold versus imipenem alone. In vivo, imipenem/cilastatin/relebactam initiation at 2 h post-challenge significantly reduced BCC burden versus imipenem/cilastatin for one of five strains (-1.67 log colony-forming units/g; P< 0.01) at therapeutic imipenem doses and four of five strains at subtherapeutic imipenem doses (-1.19 to -1.93 log colony-forming units/g; all P< 0.05).
CONCLUSIONS: Imipenem/relebactam effectively inhibited the growth of BCC isolates in vitro and reduced bacterial burden of BCC isolates in vivo. There are no interpretive susceptibility criteria for imipenem/relebactam against BCC; however, these results warrant further investigation in clinical studies.
METHODS: BCC isolates were collected as part of the Study for Monitoring Antimicrobial Resistance Trends global surveillance program from 2016 to 2019 and 2020 to 2022. Susceptibility of isolates to imipenem and imipenem/relebactam was tested in vitro, and the effects of imipenem/cilastatin/relebactam on BCC burden were evaluated in vivo.
RESULTS: In total, 346 and 293 BCC isolates were collected from 2016 to 2019 and 2020 to 2022, respectively, the most common were B. cepacia (2016-2019: n = 145/346; 2020-2022: n = 124/293) and B. cenocepacia (2016-2019: n = 137/346; 2020-2022: n = 119/293). In vitro, imipenem/relebactam reduced 50% and 90% minimum inhibitory concentrations for BCC isolates by 8-16-fold versus imipenem alone. In vivo, imipenem/cilastatin/relebactam initiation at 2 h post-challenge significantly reduced BCC burden versus imipenem/cilastatin for one of five strains (-1.67 log colony-forming units/g; P< 0.01) at therapeutic imipenem doses and four of five strains at subtherapeutic imipenem doses (-1.19 to -1.93 log colony-forming units/g; all P< 0.05).
CONCLUSIONS: Imipenem/relebactam effectively inhibited the growth of BCC isolates in vitro and reduced bacterial burden of BCC isolates in vivo. There are no interpretive susceptibility criteria for imipenem/relebactam against BCC; however, these results warrant further investigation in clinical studies.